出典: meddic

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2014/11/11 08:50:21」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.


  • Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms.
  • Espasandin Y1, Glembotsky A, Grodzielski M, Lev P, Goette N, Molinas F, Marta R, Heller P.
  • Journal of thrombosis and haemostasis : JTH.J Thromb Haemost.2015 Jan 20. doi: 10.1111/jth.12850. [Epub ahead of print]
  • BACKGROUND AND OBJECTIVES: Anagrelide represents a treatment option for essential thrombocythemia patients. It lowers platelet counts through inhibition of megakaryocyte maturation and polyploidization, although the basis for this effect remains unclear. Based on its rapid onset of action, we assess
  • PMID 25604267
  • Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.).
  • Kreher S1, Ochsenreither S, Trappe RU, Pabinger I, Bergmann F, Petrides PE, Koschmieder S, Matzdorff A, Tiede A, Griesshammer M, Riess H; Haemostasis Working Party of the German Society of Hematology and Oncology; Austrian Society of Hematology and Oncology; Society of Thrombosis and Haemostasis Research.
  • Annals of hematology.Ann Hematol.2014 Dec;93(12):1953-63. doi: 10.1007/s00277-014-2224-8. Epub 2014 Oct 14.
  • Patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) like polycythemia vera and essential thrombocythemia are at increased risk of arterial and venous thrombosis. Strategies of prevention may consist of platelet aggregation inhibitors and/or cytoreductive agents dependin
  • PMID 25307456
  • Leukemic transformation in essential thrombocythemia.
  • Bhatt VR.
  • Future oncology (London, England).Future Oncol.2014 Dec;10(16):2593-602. doi: 10.2217/fon.14.239.
  • ABSTRACT  Essential thrombocythemia patients develop acute myeloid leukemia (AML) at a rate of 1-4% during a median follow-up of 7-10 years. The risk increases with advanced age, anemia, platelet count ≥1000 × 10(9)/l, the presence of ≥2 somatic mutations and after the first decade of diagnos
  • PMID 25531047


  • アナグレライド
  • 本態性血小板血症に対するアナグレリドの有効性と安全性
  • 本態性血小板血症の治療 : anagrelide vs.ハイドロキシウレア


Anagrelide (Agrylin/Xagrid, Shire) is a drug used for the treatment of essential thrombocytosis (ET; essential thrombocythemia), or overproduction of blood platelets. It also has been used in the treatment of chronic myeloid leukemia.
Features information about dosage, usage, warnings, and side effects.



拡張検索anagrelide hydrochloride



anagrelideanagrelide hydrochloride

anagrelide hydrochloride」